A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Ramaswamy Govindan, MD
Status
Terminated
Date Opened To Accrual
November 04 2013
Date Closed to Accrual
December 20 2017
Date of Study Termination
June 04 2018
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess whether patients with unresectable local-regionally advanced NSCLC treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone
Patient Population
Histologically or cytologically confirmed non-squamous NSCLC; unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm N2 or N3 disease.
Target Accrual
234
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.